AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 23840001 — intervention group
Group type: EXPERIMENTAL
Intervention: Second challenge with C. jejuni CG8421
Number of subjects: 15
Study 23840001 — intervention group
Group type: EXPERIMENTAL
Intervention: Immune responses after primary infection
Number of subjects: 15
Study 23840124 — intervention group
Group type: EXPERIMENTAL
Intervention: Mitochondrial ATP 6 and 8 polymorphisms in patients with IBS-D
Number of subjects: 28
Study 23840124 — intervention group
Group type: COMPARATOR
Intervention: Healthy subjects (control group)
Number of subjects: 28
Study 23840124 — intervention group
Group type: EXPERIMENTAL
Intervention: Mitochondrial DNA change at 8860
Number of subjects: 28
Study 23840124 — intervention group
Group type: EXPERIMENTAL
Intervention: 8701 polymorphism
Number of subjects: 28
Study 23840618 — intervention group
Group type: EXPERIMENTAL
Intervention: MVA85A vaccine (first dose) in ART naïve subjects
Number of subjects: 24
Study 23840618 — intervention group
Group type: EXPERIMENTAL
Intervention: MVA85A vaccine (second dose) in ART naïve subjects
Number of subjects: 24
Study 23840618 — intervention group
Group type: EXPERIMENTAL
Intervention: MVA85A vaccine (first dose) in subjects on ART
Number of subjects: 24
Study 23840618 — intervention group
Group type: EXPERIMENTAL
Intervention: MVA85A vaccine (two doses) in ART naïve subjects
Number of subjects: 24
Study 23840618 — intervention group
Group type: EXPERIMENTAL
Intervention: Safety evaluation (local and systemic AEs)
Number of subjects: 24
Study 23840618 — intervention group
Group type: EXPERIMENTAL
Intervention: Monitoring of CD4 count and HIV RNA load
Number of subjects: 24
Study 23841031 — intervention group
Group type: EXPERIMENTAL
Intervention: Rigosertib (ON 01910.Na) administered as a 3-day continuous infusion every 2 weeks at escalating doses (50, 100, 150, 250, 325, 400, 650, 850, 1,050, 1,375, 1,700 mg/m(2)/24h).
Number of subjects: 28
Study 23842023 — intervention group
Group type: EXPERIMENTAL
Intervention: Digital Health Feedback System (DHFS)
Number of subjects: 28
Study 23842041 — intervention group
Group type: EXPERIMENTAL
Intervention: Sunitinib therapy
Number of subjects: 23
Study 23842457 — intervention group
Group type: EXPERIMENTAL
Intervention: Noniodized salt
Number of subjects: 9412
Study 23842457 — intervention group
Group type: EXPERIMENTAL
Intervention: Mild salt appetite
Number of subjects: 9412
Study 23842457 — intervention group
Group type: EXPERIMENTAL
Intervention: Neither iodized salt nor milk
Number of subjects: 9412
Study 23842457 — intervention group
Group type: EXPERIMENTAL
Intervention: Low urinary iodine concentration (UIC)
Number of subjects: 9412
Study 23844897 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk factors for recurrence
Number of subjects: 322
Study 23844897 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk factors for life-threatening complications
Number of subjects: 322
Study 23845947 — intervention group
Group type: EXPERIMENTAL
Intervention: Lentiviral gene therapy using a lentiviral vector encoding functional WASP
Number of subjects: 3
Study 23845947 — intervention group
Group type: EXPERIMENTAL
Intervention: Lentiviral gene therapy
Number of subjects: 3
Study 23845948 — intervention group
Group type: EXPERIMENTAL
Intervention: Lentiviral gene therapy using a lentiviral vector to transfer a functional ARSA gene into hematopoietic stem cells (HSCs)
Number of subjects: 3
Study 23846249 — intervention group
Group type: EXPERIMENTAL
Intervention: Commercial assay for ADAMTS13 activity measurement
Number of subjects: 0
Study 23846776 — intervention group
Group type: EXPERIMENTAL
Intervention: 150 mg oral dose of dabrafenib
Number of subjects: 4
Study 23846776 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous (IV) microdose of 50 µg radiolabeled dabrafenib
Number of subjects: 4
Study 23847271 — intervention group
Group type: EXPERIMENTAL
Intervention: Transjugular intrahepatic portosystemic shunt (TIPS)
Number of subjects: 50
Study 23847271 — intervention group
Group type: COMPARATOR
Intervention: Conventional therapy (endoscopic therapy combined with non-selective β-blockers and anticoagulants)
Number of subjects: 50
Study 23847271 — intervention group
Group type: EXPERIMENTAL
Intervention: TIPS
Number of subjects: 50
Study 23847271 — intervention group
Group type: COMPARATOR
Intervention: Conventional therapy
Number of subjects: 50
Study 23847319 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrahigh-resolution optical coherence tomography
Number of subjects: 26
Study 23849084 — intervention group
Group type: EXPERIMENTAL
Intervention: Cortisol measurement in women with a current or recent experience of abuse
Number of subjects: 128
Study 23849084 — intervention group
Group type: EXPERIMENTAL
Intervention: Cortisol measurement in women living in refuge
Number of subjects: 128
Study 23849084 — intervention group
Group type: COMPARATOR
Intervention: Cortisol measurement in abuse survivors
Number of subjects: 128
Study 23850249 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-fibroatheroma lesions
Number of subjects: 609
Study 23850249 — intervention group
Group type: COMPARATOR
Intervention: Fibroatheroma lesions
Number of subjects: 609
Study 23850394 — intervention group
Group type: EXPERIMENTAL
Intervention: Mirabegron 50mg
Number of subjects: 11
Study 23850394 — intervention group
Group type: EXPERIMENTAL
Intervention: Mirabegron 100mg
Number of subjects: 11
Study 23850394 — intervention group
Group type: EXPERIMENTAL
Intervention: Mirabegron (both doses)
Number of subjects: 11
Study 23850394 — intervention group
Group type: COMPARATOR
Intervention: Tolterodine
Number of subjects: 11
Study 23850394 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study 23850901 — intervention group
Group type: EXPERIMENTAL
Intervention: Renal denervation (RDN)
Number of subjects: 54
Study 23850908 — intervention group
Group type: EXPERIMENTAL
Intervention: Successful cardioversion without anticoagulation or peri-procedural heparin therapy
Number of subjects: 2481
Study 23850908 — intervention group
Group type: EXPERIMENTAL
Intervention: Age
Number of subjects: 2481
Study 23850908 — intervention group
Group type: EXPERIMENTAL
Intervention: Female sex
Number of subjects: 2481
Study 23850908 — intervention group
Group type: EXPERIMENTAL
Intervention: Heart failure
Number of subjects: 2481
Study 23850908 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetes
Number of subjects: 2481
Study 23850908 — intervention group
Group type: EXPERIMENTAL
Intervention: Classification tree analysis
Number of subjects: 2481
Study 23851165 — intervention group
Group type: EXPERIMENTAL
Intervention: Stable isotope dilution liquid chromatography electrospray ionization/selected reaction monitoring/mass spectrometry (SID-LC/ESI/SRM/MS) method for quantification of keto-androgens in human serum.
Number of subjects: 0
Study 23851165 — intervention group
Group type: EXPERIMENTAL
Intervention: SID-LC/ESI/SRM/MS method
Number of subjects: 0
Study 23851165 — intervention group
Group type: COMPARATOR
Intervention: Hydroxylamine derivatization procedure coupled with tandem mass spectrometry
Number of subjects: 0
Study 23851388 — intervention group
Group type: EXPERIMENTAL
Intervention: Osteopontin combined with NT-proBNP
Number of subjects: 401
Study 23851388 — intervention group
Group type: EXPERIMENTAL
Intervention: Osteopontin
Number of subjects: 401
Study 23851388 — intervention group
Group type: COMPARATOR
Intervention: NT-proBNP
Number of subjects: 401
Study 23851911 — intervention group
Group type: EXPERIMENTAL
Intervention: Raltegravir 400 mg twice daily plus Darunavir/Ritonavir 800/100 mg once daily
Number of subjects: 15
Study 23852419 — intervention group
Group type: EXPERIMENTAL
Intervention: NR3C2 mutation carriers
Number of subjects: 39
Study 23852775 — intervention group
Group type: EXPERIMENTAL
Intervention: H-1 parvovirus (H-1PV) infection
Number of subjects: 6
Study 23852775 — intervention group
Group type: COMPARATOR
Intervention: Non-transformed infant astrocytes and neurons
Number of subjects: 6
Study 23855804 — intervention group
Group type: EXPERIMENTAL
Intervention: Cetuximab administered as loading dose and then weekly during radiotherapy (exact dosage not specified)
Number of subjects: 500
Study 23855804 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensity-modulated radiation therapy (IMRT) or 3D-dimensional radiation therapy
Number of subjects: 500
Study 23855804 — intervention group
Group type: EXPERIMENTAL
Intervention: Cetuximab
Number of subjects: 500
Study 23855804 — intervention group
Group type: EXPERIMENTAL
Intervention: Translational research program
Number of subjects: 500
Study 23856024 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment for inherited surfactant metabolism disorders (specific treatment details not provided)
Number of subjects: 0
Study 23856681 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg of alternate-day aspirin
Number of subjects: 39876
Study 23856681 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 39876
Study 23856802 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic sinus surgery (ESS)
Number of subjects: 242
Study 23856802 — intervention group
Group type: COMPARATOR
Intervention: Continued medical management
Number of subjects: 242
Study 23857643 — intervention group
Group type: EXPERIMENTAL
Intervention: Restorations placed in previously unrestored tooth surfaces
Number of subjects: 4672
Study 23857643 — intervention group
Group type: EXPERIMENTAL
Intervention: Outcomes within individual patients (tooth surfaces affected by caries lesions)
Number of subjects: 4672
Study 23857959 — intervention group
Group type: EXPERIMENTAL
Intervention: Sepantronium Bromide (10 mg/m(2)/day, continuous intravenous infusion over 72 hours)
Number of subjects: 41
Study 23857959 — intervention group
Group type: COMPARATOR
Intervention: Carboplatin (AUC6) and Paclitaxel (200 mg/m(2))
Number of subjects: 41
Study 23857966 — intervention group
Group type: EXPERIMENTAL
Intervention: Pazopanib (tablet formulation) administered once daily in 28-day cycles at four dose levels (275 to 600 mg/m(2))
Number of subjects: 51
Study 23857966 — intervention group
Group type: EXPERIMENTAL
Intervention: Pazopanib (tablet formulation)
Number of subjects: 51
Study 23860199 — intervention group
Group type: EXPERIMENTAL
Intervention: Imatinib mesylate 400 mg per day for 1 year
Number of subjects: 106
Study 23860199 — intervention group
Group type: COMPARATOR
Intervention: Historical controls
Number of subjects: 106
Study 23860535 — intervention group
Group type: EXPERIMENTAL
Intervention: Pemetrexed 500 mg/m², Carboplatin AUC 5 mg/ml/min, Bevacizumab 15 mg/kg every 21 days for six cycles followed by maintenance Bevacizumab
Number of subjects: 76
Study 23860535 — intervention group
Group type: COMPARATOR
Intervention: Standard pemetrexed/platinum combinations (not explicitly tested in this trial)
Number of subjects: 76
Study 23860537 — intervention group
Group type: EXPERIMENTAL
Intervention: Lenvatinib 4 mg BID with carboplatin/paclitaxel
Number of subjects: 28
Study 23860537 — intervention group
Group type: EXPERIMENTAL
Intervention: Lenvatinib 6 mg BID with carboplatin/paclitaxel
Number of subjects: 28
Study 23860537 — intervention group
Group type: EXPERIMENTAL
Intervention: Lenvatinib with carboplatin/paclitaxel
Number of subjects: 28
Study 23861180 — intervention group
Group type: EXPERIMENTAL
Intervention: Citalopram (SSRI treatment)
Number of subjects: 0
Study 23861247 — intervention group
Group type: EXPERIMENTAL
Intervention: T-cell receptor-engineered lymphocytes
Number of subjects: 0
Study 23861248 — intervention group
Group type: EXPERIMENTAL
Intervention: Rituximab (375 mg/m² IV) administered at 3, 6, 9, and 12 months after transplantation
Number of subjects: 65
Study 23861512 — intervention group
Group type: EXPERIMENTAL
Intervention: OAC+ASA
Number of subjects: 7347
Study 23861512 — intervention group
Group type: COMPARATOR
Intervention: OAC
Number of subjects: 7347
Study 23863898 — intervention group
Group type: EXPERIMENTAL
Intervention: Allogeneic hematopoietic stem cell transplantation (alloHSCT)
Number of subjects: 124
Study 23863898 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous hematopoietic stem cell transplantation (autoHSCT)
Number of subjects: 124
Study 23863898 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy
Number of subjects: 124
Study 23863898 — intervention group
Group type: EXPERIMENTAL
Intervention: Reinduction therapy followed by alloHSCT
Number of subjects: 124
Study 23864214 — intervention group
Group type: EXPERIMENTAL
Intervention: Education programme targeted at school children to reduce salt intake, lasting approximately 4.5 months.
Number of subjects: 840
Study 23864214 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified in detail).
Number of subjects: 840
Study 23865483 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardized methods for data collection (anamnestic, clinical, laboratory, imaging, ultrasound) in ischemic stroke patients
Number of subjects: 400
Study 23865516 — intervention group
Group type: EXPERIMENTAL
Intervention: Ubiquitin C-terminal hydrolase L1 (UCH-L1)
Number of subjects: 206
Study 23865516 — intervention group
Group type: EXPERIMENTAL
Intervention: Glial fibrillary acidic protein (GFAP)
Number of subjects: 206
Study 23865516 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined analysis of UCH-L1 and GFAP
Number of subjects: 206
Study 23865516 — intervention group
Group type: EXPERIMENTAL
Intervention: GFAP
Number of subjects: 206
Study 23865516 — intervention group
Group type: EXPERIMENTAL
Intervention: UCH-L1
Number of subjects: 206
Study 23866070 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma fibulin-1 in diabetic group
Number of subjects: 180
Study 23866070 — intervention group
Group type: COMPARATOR
Intervention: Plasma fibulin-1 in control group
Number of subjects: 180
Study 23866070 — intervention group
Group type: EXPERIMENTAL
Intervention: Total study sample analysis
Number of subjects: 180
Study 23866070 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjusted analysis in diabetes group
Number of subjects: 180
Study 23866188 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 23866828 — intervention group
Group type: EXPERIMENTAL
Intervention: Everolimus 1.5 mg/day + reduced-dose cyclosporine
Number of subjects: 122
Study 23866828 — intervention group
Group type: COMPARATOR
Intervention: Mycophenolate mofetil (MMF) 2 g/day + standard dose cyclosporine
Number of subjects: 122
Study 23867137 — intervention group
Group type: EXPERIMENTAL
Intervention: Mexican-American adolescent women
Number of subjects: 559
Study 23867137 — intervention group
Group type: COMPARATOR
Intervention: African-American adolescent women
Number of subjects: 559
Study 23867211 — intervention group
Group type: EXPERIMENTAL
Intervention: Denosumab 120 mg subcutaneously every 4 weeks with loading doses on days 8 and 15 of the first cycle (for cohorts 1 and 2)
Number of subjects: 282
Study 23867211 — intervention group
Group type: EXPERIMENTAL
Intervention: Denosumab 120 mg subcutaneously every 4 weeks with loading doses on days 8 and 15 of the first cycle (for cohort 2)
Number of subjects: 282
Study 23867211 — intervention group
Group type: EXPERIMENTAL
Intervention: Denosumab
Number of subjects: 282
Study 23867552 — intervention group
Group type: EXPERIMENTAL
Intervention: CD40L/IFN-γ-matured, IL-12p70-producing DCs
Number of subjects: 7
Study 23867776 — intervention group
Group type: EXPERIMENTAL
Intervention: ROTEM analysis at T1 (10 min after heparin administration)
Number of subjects: 20
Study 23867776 — intervention group
Group type: COMPARATOR
Intervention: INTEM at T0 compared to HEPTEM at T1
Number of subjects: 20
Study 23867776 — intervention group
Group type: EXPERIMENTAL
Intervention: EXTEM and HEPTEM at T2 (end of CPB)
Number of subjects: 20
Study 23867776 — intervention group
Group type: EXPERIMENTAL
Intervention: EXTEM and INTEM at T3 (10 min after protamine)
Number of subjects: 20
Study 23867999 — intervention group
Group type: EXPERIMENTAL
Intervention: Carboplatin
Number of subjects: 87
Study 23867999 — intervention group
Group type: EXPERIMENTAL
Intervention: Deleterious BRCA1/2 mutation
Number of subjects: 87
Study 23867999 — intervention group
Group type: EXPERIMENTAL
Intervention: Cumulative exposure to carboplatin
Number of subjects: 87
Study 23867999 — intervention group
Group type: COMPARATOR
Intervention: History of HSR
Number of subjects: 87
Study 23868427 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous injection of HPPH (4.0 mg/m2), followed by activation with 665-nm laser light in the surgical bed immediately after tumor resection.
Number of subjects: 16
Study 23868881 — intervention group
Group type: EXPERIMENTAL
Intervention: Repetitive Behavior Scale-Revised (caregiver report) in children with autism
Number of subjects: 0
Study 23868881 — intervention group
Group type: COMPARATOR
Intervention: Repetitive Behavior Scale-Revised (caregiver report) in children with nonspectrum developmental delays or typical development
Number of subjects: 0
Study 23869677 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin detemir (once-daily)
Number of subjects: 14611
Study 23870026 — intervention group
Group type: EXPERIMENTAL
Intervention: Aortic calcifications (AC)
Number of subjects: 253
Study 23870026 — intervention group
Group type: EXPERIMENTAL
Intervention: Carotid-femoral pulse wave velocity (PWV)
Number of subjects: 253
Study 23870026 — intervention group
Group type: EXPERIMENTAL
Intervention: Receiver operating characteristics for AC
Number of subjects: 253
Study 23870026 — intervention group
Group type: EXPERIMENTAL
Intervention: Receiver operating characteristics for PWV
Number of subjects: 253
Study 23870704 — intervention group
Group type: EXPERIMENTAL
Intervention: Maribavir (MBV) 400 mg p.o. twice per day
Number of subjects: 1
Study 23870704 — intervention group
Group type: COMPARATOR
Intervention: Ganciclovir, foscarnet, cidofovir, leflunomide, and maribavir
Number of subjects: 1
Study 23871094 — intervention group
Group type: EXPERIMENTAL
Intervention: HDWL endoscopy
Number of subjects: 84
Study 23871094 — intervention group
Group type: EXPERIMENTAL
Intervention: HDWL plus i-Scan
Number of subjects: 84
Study 23871427 — intervention group
Group type: EXPERIMENTAL
Intervention: Neurocutaneous island flap
Number of subjects: 12
Study 23872309 — intervention group
Group type: EXPERIMENTAL
Intervention: High-coverage genome sequencing of DNA from peripheral blood granulocytes and cultured skin fibroblasts.
Number of subjects: 1
Study 23872309 — intervention group
Group type: COMPARATOR
Intervention: Re-sequencing of six genes (CARD6, BRD2, KIAA0355, CAP2, SOX30, MFRP) in 178 patients with polycythemia vera, essential thrombocythemia, and myelofibrosis.
Number of subjects: 1
Study 23872668 — intervention group
Group type: EXPERIMENTAL
Intervention: Allogeneic mesenchymal stromal cells (MSCs) administered intravenously at a dosage of 2 × 10(6) cells/kg body weight weekly for 4 weeks.
Number of subjects: 16
Study 23872668 — intervention group
Group type: COMPARATOR
Intervention: Control group not applicable as this is an open-label study with no control.
Number of subjects: 16
Study 23873169 — intervention group
Group type: EXPERIMENTAL
Intervention: e-Cigarette use for 6 months
Number of subjects: 40
Study 23874743 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-risk group (62% of women)
Number of subjects: 727
Study 23874743 — intervention group
Group type: COMPARATOR
Intervention: High-risk group (38% of women)
Number of subjects: 727
Study 23874743 — intervention group
Group type: EXPERIMENTAL
Intervention: College degree or above
Number of subjects: 727
Study 23874743 — intervention group
Group type: EXPERIMENTAL
Intervention: Older age
Number of subjects: 727
Study 23874743 — intervention group
Group type: EXPERIMENTAL
Intervention: Hispanic ethnicity
Number of subjects: 727
Study 23874743 — intervention group
Group type: EXPERIMENTAL
Intervention: APOE-ε4 prevalence
Number of subjects: 727
Study 23874777 — intervention group
Group type: EXPERIMENTAL
Intervention: New RBC units (stored for less than 14 days)
Number of subjects: 1929
Study 23874777 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermediate RBC units (stored between 14 and 28 days)
Number of subjects: 1929
Study 23874777 — intervention group
Group type: EXPERIMENTAL
Intervention: Old RBC units (stored for more than 28 days)
Number of subjects: 1929
Study 23874777 — intervention group
Group type: EXPERIMENTAL
Intervention: RBC transfusion
Number of subjects: 1929
Study 23874777 — intervention group
Group type: EXPERIMENTAL
Intervention: Duration of storage of transfused RBC
Number of subjects: 1929
Study 23874828 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 PfSPZ-infected Anopheles stephensi mosquitoes
Number of subjects: 19
Study 23875619 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical predictive score for cancer diagnosis
Number of subjects: 540
Study 23876210 — intervention group
Group type: EXPERIMENTAL
Intervention: Entecavir (0.5 or 1.0 mg)
Number of subjects: 2600
Study 23876467 — intervention group
Group type: EXPERIMENTAL
Intervention: Undetectable levels of high-sensitivity cardiac Troponin (hs-cTnT)
Number of subjects: 2072
Study 23876467 — intervention group
Group type: EXPERIMENTAL
Intervention: hs-cTnI Siemens
Number of subjects: 2072
Study 23876467 — intervention group
Group type: EXPERIMENTAL
Intervention: hs-cTnI Beckman Coulter
Number of subjects: 2072
Study 23876467 — intervention group
Group type: EXPERIMENTAL
Intervention: hs-cTnI Abbott
Number of subjects: 2072
Study 23876904 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D levels in critically ill patients (ICU sepsis and ICU control group)
Number of subjects: 206
Study 23876904 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D levels in septic patients
Number of subjects: 206
Study 23876904 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D levels and disease severity assessment
Number of subjects: 206
Study 23876904 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D levels and 28-day survival
Number of subjects: 206
Study 23876904 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D levels and 90-day survival
Number of subjects: 206
Study 23876904 — intervention group
Group type: EXPERIMENTAL
Intervention: APACHE II and SAPS II scores
Number of subjects: 206
Study 23877326 — intervention group
Group type: EXPERIMENTAL
Intervention: Free abdominal air detected on radiograph at 2 days after surgery
Number of subjects: 648
Study 23877326 — intervention group
Group type: EXPERIMENTAL
Intervention: Free abdominal air detected on radiograph at 3 days after surgery
Number of subjects: 648
Study 23877367 — intervention group
Group type: EXPERIMENTAL
Intervention: Obese I (BMI 30 to 34.9)
Number of subjects: 405
Study 23877367 — intervention group
Group type: EXPERIMENTAL
Intervention: Obese III (BMI > 40)
Number of subjects: 405
Study 23877367 — intervention group
Group type: COMPARATOR
Intervention: Normal weight
Number of subjects: 405
Study 23878017 — intervention group
Group type: EXPERIMENTAL
Intervention: Roux-en-Y pancreaticojejunostomy (PJ) in a duct-to-mucosa fashion
Number of subjects: 26
Study 23878017 — intervention group
Group type: COMPARATOR
Intervention: No anastomosis
Number of subjects: 26
Study 23878046 — intervention group
Group type: EXPERIMENTAL
Intervention: Ecallantide (30 mg subcutaneously)
Number of subjects: 29
Study 23878046 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 29